These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 25720063)

  • 1. Innate immune responses in the brain of sphingolipid lysosomal storage diseases.
    Vitner EB; Futerman AH; Platt N
    Biol Chem; 2015 Jun; 396(6-7):659-67. PubMed ID: 25720063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of brain innate immune response in lysosomal storage disorders: fundamental process or evolutionary side effect?
    Vitner EB
    FEBS Lett; 2020 Nov; 594(22):3619-3631. PubMed ID: 33131047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expanding boundaries of sphingolipid lysosomal storage diseases; insights from Niemann-Pick disease type C.
    Platt FM
    Biochem Soc Trans; 2023 Oct; 51(5):1777-1787. PubMed ID: 37844193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Finding pathogenic commonalities between Niemann-Pick type C and other lysosomal storage disorders: Opportunities for shared therapeutic interventions.
    Yañez MJ; Marín T; Balboa E; Klein AD; Alvarez AR; Zanlungo S
    Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165875. PubMed ID: 32522631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From sheep to mice to cells: tools for the study of the sphingolipidoses.
    Zigdon H; Meshcheriakova A; Futerman AH
    Biochim Biophys Acta; 2014 Aug; 1841(8):1189-99. PubMed ID: 24607565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of
    Sellin J; Schulze H; Paradis M; Gosejacob D; Papan C; Shevchenko A; Psathaki OE; Paululat A; Thielisch M; Sandhoff K; Hoch M
    Dis Model Mech; 2017 Jun; 10(6):737-750. PubMed ID: 28389479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concentrations of an activator protein for sphingolipid hydrolysis in liver and brain samples from patients with lysosomal storage diseases.
    Inui K; Wenger DA
    J Clin Invest; 1983 Nov; 72(5):1622-8. PubMed ID: 6415115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Therapy of Sphingolipid Metabolic Disorders.
    Shaimardanova AA; Solovyeva VV; Issa SS; Rizvanov AA
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Comparative Study on the Alterations of Endocytic Pathways in Multiple Lysosomal Storage Disorders.
    Rappaport J; Manthe RL; Solomon M; Garnacho C; Muro S
    Mol Pharm; 2016 Feb; 13(2):357-368. PubMed ID: 26702793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune dysfunction in Niemann-Pick disease type C.
    Platt N; Speak AO; Colaco A; Gray J; Smith DA; Williams IM; Wallom KL; Platt FM
    J Neurochem; 2016 Jan; 136 Suppl 1(Suppl Suppl 1):74-80. PubMed ID: 25946402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demographic characteristics and distribution of lysosomal storage disorder subtypes in Eastern China.
    Chen X; Qiu W; Ye J; Han L; Gu X; Zhang H
    J Hum Genet; 2016 Apr; 61(4):345-9. PubMed ID: 26740238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LC-MS/MS multiplex analysis of lysosphingolipids in plasma and amniotic fluid: A novel tool for the screening of sphingolipidoses and Niemann-Pick type C disease.
    Pettazzoni M; Froissart R; Pagan C; Vanier MT; Ruet S; Latour P; Guffon N; Fouilhoux A; Germain DP; Levade T; Vianey-Saban C; Piraud M; Cheillan D
    PLoS One; 2017; 12(7):e0181700. PubMed ID: 28749998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of infiltrating peripheral myeloid cells in the brains of mouse models of lysosomal storage disorders.
    Cho SM; Vardi A; Platt N; Futerman AH
    J Neurochem; 2019 Mar; 148(5):625-638. PubMed ID: 29900534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune system irregularities in lysosomal storage disorders.
    Castaneda JA; Lim MJ; Cooper JD; Pearce DA
    Acta Neuropathol; 2008 Feb; 115(2):159-74. PubMed ID: 17924126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolomic Studies of Lipid Storage Disorders, with Special Reference to Niemann-Pick Type C Disease: A Critical Review with Future Perspectives.
    Percival BC; Gibson M; Wilson PB; Platt FM; Grootveld M
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The biochemistry of sphingolipid storage diseases.
    Sandhoff K
    Angew Chem Int Ed Engl; 1977 May; 16(5):273-85. PubMed ID: 406814
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular facets of sphingolipids: mediators of diseases.
    Ozbayraktar FB; Ulgen KO
    Biotechnol J; 2009 Jul; 4(7):1028-41. PubMed ID: 19579220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer and sphingolipid storage disease therapy using novel synthetic analogs of sphingolipids.
    Gatt S; Dagan A
    Chem Phys Lipids; 2012 May; 165(4):462-74. PubMed ID: 22387097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sphingolipid lysosomal storage diseases: from bench to bedside.
    Abed Rabbo M; Khodour Y; Kaguni LS; Stiban J
    Lipids Health Dis; 2021 May; 20(1):44. PubMed ID: 33941173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sphingolipids and neuronal degeneration in lysosomal storage disorders.
    Grassi S; Chiricozzi E; Mauri L; Sonnino S; Prinetti A
    J Neurochem; 2019 Mar; 148(5):600-611. PubMed ID: 29959861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.